首页> 外文期刊>The Journal of Urology >Phase II trial of neoadjuvant nab-paclitaxel in high risk patients with prostate cancer undergoing radical prostatectomy.
【24h】

Phase II trial of neoadjuvant nab-paclitaxel in high risk patients with prostate cancer undergoing radical prostatectomy.

机译:新辅助性nab-紫杉醇在高危前列腺癌患者中接受根治性前列腺切除术的II期试验。

获取原文
获取原文并翻译 | 示例
       

摘要

PURPOSE: Taxane based chemotherapy has activity in advanced prostate cancer but previous studies of neoadjuvant docetaxel demonstrated a prostate specific antigen response with no obvious antitumor activity. The efficacy and safety of neoadjuvant albumin-bound paclitaxel (nab-paclitaxel, Abraxane), a novel nanoparticle based formulation, were assessed in patients with high risk, locally advanced prostate cancer. MATERIALS AND METHODS: Eligible patients had locally advanced prostatic adenocarcinoma, clinical stage cT2b or greater, Gleason score 8 or greater, or serum prostate specific antigen 15 ng/ml or greater without metastatic disease. Patients received 2 cycles of 150 mg/m(2) nab-paclitaxel weekly for 3 weeks during each 4-week cycle, followed by radical prostatectomy with bilateral lymphadenectomy. Efficacy assessments included pathological and prostate specific antigen response. RESULTS: A total of 19 patients completed neoadjuvant therapy and 18 underwent radical prostatectomy. Median pretreatment prostate specific antigen was 8.5 ng/ml and median Gleason score was 8. Despite the lack of complete pathological responses 5 of 18 patients (28%) had organ confined disease and 9 of 18 (50%) had specimen confined disease. Post-chemotherapy prostate specific antigen was decreased in 18 of 19 (95%) patients and median decrease was 2.9 ng/ml (35%, p <0.001). An initial prostate specific antigen after radical prostatectomy of 0.02 ng/ml or less was achieved in 17 of 18 (94%) patients. There were no significant perioperative complications. Cytoplasmic vacuolization (focal in 10 and extensive in 7) was evident in all but 1 patient (94%). Ten patients (56%) had grade 3 and 1 had grade 4 neutropenia with no febrile neutropenia. CONCLUSIONS: Neoadjuvant nab-paclitaxel was well tolerated. Similar to our experience with neoadjuvant docetaxel there were no pathological complete responses, although a possible histological antitumor effect was observed.
机译:目的:基于紫杉烷类的化学疗法在晚期前列腺癌中具有活性,但是先前对新辅助多西他赛的研究表明,前列腺特异性抗原反应没有明显的抗肿瘤活性。在具有高风险,局部晚期前列腺癌的患者中评估了新辅助结合白蛋白的紫杉醇(nab-紫杉醇,Abraxane)的有效性和安全性,这是一种新型的基于纳米颗粒的制剂。材料与方法:符合条件的患者患有局部晚期前列腺癌,临床分期cT2b或更高,格里森评分8或更高,或血清前列腺特异性抗原15 ng / ml或更高而无转移性疾病。在每个4周的周期中,患者每周接受2个周期的150 mg / m(2)纳布-紫杉醇的治疗,持续3周,然后进行根治性前列腺切除术和双侧淋巴结清扫术。功效评估包括病理和前列腺特异性抗原反应。结果:共有19例患者完成了新辅助治疗,其中18例接受了根治性前列腺切除术。治疗前前列腺特异性抗原的中位数为8.5 ng / ml,中位格里森评分为8。尽管缺乏完全的病理反应,但18例患者中有5例(28%)患有器官受限疾病,18例中有9例(50%)患有标本受限疾病。化学治疗后19名患者中有18名(95%)的前列腺特异性抗原降低,中位降低为2.9 ng / ml(35%,p <0.001)。在18例患者中,有17例(94%)实现了前列腺癌根治术后的0.02 ng / ml或更低的初始前列腺特异性抗原。没有明显的围手术期并发症。除1名患者外,其他所有患者(94%)均可见细胞质空泡(局灶性10例,广泛型7例)。 10名患者(56%)患有3级,1名患有4级中性粒细胞减少,没有发热性中性粒细胞减少。结论:新辅助nab-紫杉醇耐受性良好。与我们对新辅助多西他赛的经验相似,尽管观察到可能的组织学抗肿瘤作用,也没有病理学上的完全反应。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号